Yea. I certainly do not know Paul intimately and what his leadership attributes are. I have worked for a number of public companies and have been a direct report to CEOs - many diff kinds and not all were very astute with investor communit or institutions. CFOs sometime filled in well.
Paul may just be one of those CEOs that do not embrace your points very well, but good at other things such as strategic vision, hiring best talent, and operational excellence. You would think his team could fill in some of Paul's shortcomings.
At the end, sooner or later, with execution, market will wake up to Atrs. Agree that it could be facilitated better.
I still hope that at least Paul will not let me/us down on fda approval in 3 weeks.
Market Data 
Markets 
AI
